Facial appearance and metabolic health biomarkers in women

Agnieszka Żelaźniewicz*, Judyta Nowak, Patrycja Łącka & Bogusław Pawłowski

Facial appearance has been suggested to provide an honest cue of an individual's biological condition. However, there is little direct evidence that facial attractiveness reflects actual health. Here we tested if facial appearance is related with metabolic health biomarkers. Face photographs of 161 healthy, young women ($M_{\text{age}} = 28.59$, $SD_{\text{age}} = 2.34$) were assessed in terms of perceived attractiveness and health. Metabolic health was evaluated based on levels of markers of lipid and glucose metabolism balance, liver functioning, and inflammation. BMI, testosterone (T), and estradiol (E2) levels were controlled. Facial attractiveness, but not health, was negatively related with lipid profile components detrimental to health (total cholesterol, LDL, triglycerides) but not with relatively protective for health HDL. When controlled for BMI, E2, and T, only the relationship between attractiveness and triglycerides remained significant. Facial appearance was unrelated with glucose metabolism, liver functioning, and inflammatory markers. The results suggest, that for healthy women of reproductive age, such measures as BMI and sex hormone levels may be better predictors of attractiveness, compared to measures of metabolic health. Markers of lipid, glucose homeostasis, liver functioning or low-grade inflammation may be rather indicators of future health, of lesser importance in mating context, thus only modestly reflected in facial appearance.

Evolutionary theories propose that facial attractiveness is a cue of an individual's biological condition. Thus, facial attractiveness and individual characteristics, cross-culturally perceived as attractive, such as sexual dimorphism, symmetry, averageness, carotenoid-linked skin colour, and homogenous skin texture are expected to develop and be displayed only in individuals with good health and high fertility, and to correlate with various measures of biological condition, allowing for the best possible partner selection.

Although perceived facial attractiveness is widely recognized as such honest cue of an individual's health, there are relatively few studies testing this assumption directly. Furthermore, the results of these studies are ambiguous, indicating none or positive correlation between perceived attractiveness and health measures, however inconsistent across sexes or the studied measures. Male facial attractiveness has been suggested to reflect the strength of antibody response to vaccination and cytokine response after stimulation with lipopolysaccharide, two direct measures of immune functioning. Furthermore, Gangestad et al. showed that male facial attractiveness, symmetry and masculinity are negatively related with oxidative stress level, an important physiological measure of general body functioning, underlying many pathological processes and diseases. For women, the results are more ambiguous and, in fact, there is little direct evidence that female facial appearance signals immunity or health. Some research has shown that women's facial attractiveness correlates negatively with cortisol level and percentage of body fat but not with the strength of antibody response to vaccination or salivary immunoglobulin A level. Also, Foo et al. showed that neither attractiveness nor its components (facial femininity and adiposity) were related to immune functioning or oxidative stress level in women. However, other studies have suggested that women's facial femininity reflects better physical health and fewer infections per year or fewer past health problems.

Most of the research in this area is characterized by relatively infrequent use of non-student samples and focus on health markers related mainly with innate or acquired immunity, self-reported infection frequency, sex hormones levels or oxidative balance, neglecting other important factors, undercurrent and future health, such as metabolic homeostasis, that may also be reflected in physical appearance and shape preferences in mate choice context. From evolutionary point of view, health can be understood as an organism's optimal functioning, resulting not only from many physiological processes and body functions, but also from biological trade-offs between them, occurring throughout the life course, ensuring maximal possible fitness in given genetic and environmental conditions. As such, it may be difficult to reliably evaluate an individual's

Department of Human Biology, University of Wrocław, ul. Kuźnicza 35, 50-138 Wrocław, Poland. *email: agnieszka.zelazniewicz@uwr.edu.pl
biological condition, based on a single health component, and studies on the relationship between physical attractiveness and other than immunity health components may help to resolve discrepancies in previous results.

So far, no study has examined the relationship between facial appearance and markers of metabolic health, underlying many current and future health problems and related with the crucial components of an individual’s biological condition (e.g. immunity and/or fertility). Lipid profile is strongly linked not only with cardio-metabolic health, mortality risk, but also with fertility19, and as such, may predict women’s reproductive success. For instance, cholesterol is a substrate for estradiol and progesterone synthesis20, directly related with female fecundity21. Furthermore, maternal cholesterol metabolism during pregnancy is crucial for fetus development and has a long-term impact on offspring’s adult health.22. Also, glucose metabolism may be reflected in facial appearance, not only as a major metabolic determinant of the ageing process23 and longevity24–26, but also due to its relationship with skin ageing27,28, and perceived age29. Furthermore, liver malfunction may be quickly reflected in facial appearance, as it can result in various cutaneous and mucosal changes, as well as in pruritus and abnormal hair growth, that can be easily seen with the naked eye30. Also, chronic low-grade inflammation, i.e. a minor elevation in the baseline concentration of inflammatory markers such as C-reactive protein (CRP) or interleukin 6 (IL-6), is recognized as an important factor, underlying many common diseases31,32, fertility problems33, and ageing processes34.

Here, we tested if a woman’s facial appearance is a cue to her metabolic health. In a sample of non-student women of reproductive age, we investigated the relationship between facial attractiveness and: (1) serum lipid profile (total cholesterol, high density lipoprotein (HDLC), low density lipoprotein (LDL), triglycerides levels), (2) glucose homeostasis markers [glycated hemoglobin (HbA1C), HOMA-IR score (homeostatic model assessment for insulin resistance)], the connecting peptide (C-peptide), (3) liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST)], and (4) non-specific inflammation markers [high sensitivity CRP (hsCRP), IL-6]. We hypothesized that facial attractiveness is negatively related to the levels of proatherogenic cholesterol, triglycerides and LDL and positively related to antiatherogenic HDLC. We hypothesized, that levels of such measures of glucose homeostasis as HbA1C, HOMAI-IR, and C-peptide negatively predict women’s facial attractiveness. Furthermore, we hypothesized that liver enzymes, hsCRP and IL-6 levels are negatively related with facial attractiveness. Additionally, as estradiol35 and testosterone46 may impact not only a woman’s facial attractiveness, but also levels of health biomarkers used in this study47–50, we included these hormones in the analyses. In order to control for the possible impact of menstrual cycle on metabolic health markers51–53, women were invited to participate in the study in the early follicular phase, recommended for evaluation of inflammatory markers such as C-reactive protein (CRP) or interleukin 6 (IL-6), is recognized as an important factor, underlying many common diseases54,55, fertility problems36, and ageing processes37.

Material and methods

This research was a part of a broader project on women’s health, conducted on 211 women (Mage = 28.51, SDage = 2.37) from a western, urban population. Participants were recruited by information in local newspapers, radio, social networks and advertisement. The protocol used to recruit participants and collect data was approved by local ethics committee. The general purpose of the study was explained and informed, written consent was obtained for participation in the study and use of data for scientific purposes from all participants.

Participants and general procedure. Face photographs and complete results of blood analysis were available for 171 women between 24 and 34 years old (Mage = 28.61, SDage = 2.34), constituting the study sample for this research. The criteria for inclusion were: no fertility problems (including PCOS), never been pregnant (including miscarriages), no chronic diseases (diabetes, thyroid problems, etc.), and no acute infections (cold, flu, tooth extraction, etc.). Women’s health status was verified based on medical control, blood morphology with smear and CRP level.

All women were asked to contact the research team at the 1st day of the menstrual cycle (self-assessed) and were invited to participate in the study between the 2nd and the 4th day of menstrual cycle (early follicular phase). Ten participants were excluded from the analyses due to the following reasons: (a) elevated levels of inflammation biomarkers (CRP >10 µg/ml), indicating ongoing inflammatory state (N = 4); (b) inadequate menstrual cycle day (N = 5); (c) testosterone level exceeding three standard deviation (N = 1). The final analyses included 161 women (Mage = 28.59, SDage = 2.34).

During the visit, a fasting blood sample was taken between 7:30 and 9:00 a.m. for further blood biochemical and hormonal analyses. Participants were weighed, measured and BMI was calculated. Photos of women’s faces were taken. Participants also filled personal questionnaire, containing questions on date of birth, education level, and also, in order to verify their health status, questions on past and current health problems and medication use.

Biochemical analyses of health biomarkers. Biochemical analyses of blood health markers included evaluation of: (1) lipid profile (total cholesterol, HDL, LDL, triglycerides); (2) glucose homeostasis markers (HbA1C), HOMA-IR index [calculated based on fasting glucose and insulin levels, according to the formula: insulin (mU/ml) x glucose (mmol/l)/22.5] and C-peptide level; (3) liver enzymes [alanine transaminase (ALT) and aspartate transaminase (AST)]; (4) inflammatory markers (hsCRP, hsIL-6). All measures, except inflammation markers were measured in professional analytical laboratory.

HsCRP and hsIL-6 were measured by immunoassay and commercial ELISA kit (DEMEDITEC cat. no. DE740011, and R&D cat. no. HS600B). Inter- and intra-assay precision, provided by the manufacturer, were < 6.3%, < 6.9% for hsCRP and < 9.6%, < 7.8% for hsIL-6. Assay sensitivity was 0.02 µg/ml for hsCRP and 0.039 pg/ml for hsIL-6. Sample and reagents preparation as well as assay procedures were carried out in
Hormones levels analyses. Estradiol (E2) level was assayed in certified laboratory (DIAGNOSTYKA) using ElectroChemi Luminescence immunoassay and Cobas analyzer (Roche Diagnostic) and expressed in pg/ml.

Quantitative measurement of total testosterone (tT) were determined by enzyme immunoassay using commercial kits (DEMEDITEC, cat. no. DE1559). Inter- and intra-assay coefficients of variation, provided by the manufacturer, were <10% and <4.2% respectively, with a test sensitivity 0.08 ng/mL. Assay procedure was performed in accordance the manufacturer’s instruction. Samples were assayed in duplicate and the average absorbance value was used to calculate hormone concentration. Standard curve was created by plotting absorbance values for each standard (Y axis) against its concentration (X axis). Total testosterone concentration was calculated in relation to standard curve and expressed in ng/ml.

Statistical methods. As values of health markers, E2 and tT levels were not distributed normally across participants, logarithmic values were used in the analyses. First, to explore the data, we performed zero-order correlation analyses between facial appearance and health markers (cholesterol, HDL, LDL, triglycerides, ALT, AST, Hba1C, HOMA-IR, C-peptide, hsCRP, IL-6 levels) and also controlled variables (BMI, age, tT, and E2). Benjamini–Hochberg adjustment was used to correct p-values for multiple testing. Additionally, we also run zero-order correlations between controlled variables and health biomarkers. As age was not related with facial appearance we did not include age in further analyses.

In order to reduce the number of predictors and to summarize the interrelated health markers variables we conducted Principal Component Analysis on metabolic health markers (total cholesterol, HDL, LDL, triglycerides, Hba1C, HOMA-IR, C-peptide, ALT, AST, hsCRP, and II-6 levels). After obtaining principal components (data reduction in Supplementary Materials—Table S3), we ran two multiple regressions with facial attractiveness and perceived health as dependent variables, and principal components as predictors, including BMI and sex steroids levels as controlled variables.

Analyses were performed with Statistica 12.0 software. The results were interpreted as statistically significant if p < 0.05.

Ethics statement. The research was approved by the by Ethics Committee of Lower Silesian Chamber of Physicians (2/BO/2016). The general purpose of the study was explained and written consent was obtained for participation in the study and use of data for scientific purposes from all participants. All medical procedures, including participants examination and blood collection, have been conducted by certified medical staff at the medical clinic. All procedure was consistent with the guideline included in the "Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects" formulated by World Medical Association in 2013 (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-resea rch-involving-human-subjects/).

Results
Descriptive statistics. Mean values, ranges and standard deviations of facial attractiveness and facial health assessment, health markers, age and controlled variables are presented in Table 1. Although facial attractiveness and health assessment were strongly correlated (r = 0.78, p < 0.001, 95% CI [0.71; 0.83]) test for dependen-
ent samples showed that men tended to give higher facial health ratings ($M = 4.80 \pm 0.74$) compared with facial attractiveness assessment ($M = 3.80 \pm 0.98$) ($t(160) = -20.96$, $p < 0.001$).

Zero-order correlation analyses for the relationship between health biomarkers and controlled variables are presented in Supplementary Material.

Perceived facial attractiveness and health & health biomarkers. Zero-order correlation analyses revealed that facial attractiveness correlated negatively with total cholesterol, LDL, triglycerides, BMI, and tT level and positively with E2 level. However, the correlations between facial attractiveness and total cholesterol and tT were non-significant when corrected for multiple comparisons (Supplementary Material, Table S2). There was no correlation between facial attractiveness and HDL, glucose homeostasis, markers of liver functioning, inflammatory markers. Perceived facial health was not related with lipid profile, glucose homeostasis or markers of liver functioning. There was a negative relationship between perceived health and hsCRP level, BMI and tT level and positive with E2 level (Table 2). However, the relationship between perceived health and hsCRP was not significant when $p$-value was corrected for multiple comparisons (Supplementary Materials, Table S2).

Principal component analysis returned four PCs (see supplementary material for details on data reduction—Table S3). PCA returned four PCs with eigenvalues > 1. PC1 was loaded mainly by glucose homeostasis markers

| Face attractiveness | Perceived health |
|--------------------|-----------------|
| LOG total cholesterol (mg/dl) | -0.18 0.02 [-0.32; -0.03] -0.08 0.28 [-0.23; 0.07] |
| LOG HDL (mg/dl) | 0.11 0.16 [-0.04; 0.26] 0.06 0.44 [-0.09; 0.21] |
| LOG LDL (mg/dl) | -0.21 0.009 [-0.35; -0.06] -0.11 0.15 [-0.26; 0.04] |
| LOG triglycerides (mg/dl) | -0.25 0.002 [-0.39; -0.10] -0.08 0.30 [-0.23; 0.07] |
| LOG HbA1C (%) | -0.10 0.20 [-0.25; 0.05] -0.05 0.49 [-0.20; 0.10] |
| LOG HOMA-IR | -0.10 0.21 [-0.25; 0.05] -0.12 0.13 [-0.27; 0.03] |
| LOG C-peptide (ng/ml) | -0.05 0.55 [-0.20; 0.10] 0.02 0.76 [-0.13; 0.17] |
| LOG ALT (U/l) | -0.06 0.43 [-0.21; 0.09] -0.12 0.12 [-0.27; 0.03] |
| LOG AST (U/l) | 0.02 0.78 [-0.13; 0.17] -0.04 0.60 [-0.19; 0.11] |
| LOG hsCRP (µg/ml) | -0.14 0.08 [-0.29; 0.01] -0.18 0.02 [-0.32; -0.03] |
| LOG hsIL-6 (pg/ml) | -0.10 0.19 [-0.25; 0.05] -0.09 0.24 [-0.24; 0.06] |
| BMI (kg/m²) | -0.26 <0.001 [-0.40; -0.11] -0.22 0.004 [-0.36; -0.07] |
| Age (year) | -0.03 0.67 [-0.18; 0.12] 0.08 0.31 [-0.07; 0.23] |
| LOG tTestosterone (ng/ml) | -0.16 0.04 [-0.31; -0.01] -0.22 0.006 [-0.36; -0.07] |
| LOG E2 (pg/ml) | 0.20 0.01 [0.05; 0.34] 0.24 0.002 [0.09; 0.40] |

Table 2. Correlation values for the relationship between biomarkers of health and face attractiveness and health assessment, with the corresponding $p$-values ($N = 161$). Bolded values are significant at $p < 0.05$. 

| M         | SD           | Min  | Max  |
|-----------|--------------|------|------|
| Age (year)| 28.59        | 2.34 | 25.00| 33.00|
| Total cholesterol (mg/dl)| 178.30 | 26.48 | 117.00| 242.00|
| HDL (mg/dl) | 71.79 | 15.34 | 36.00| 108.00|
| LDL (mg/dl) | 91.71 | 22.71 | 32.00| 155.00|
| Triglycerides (mg/dl) | 74.04 | 33.03 | 32.00| 270.00|
| HbA1C (%) | 5.04 | 0.20 | 4.40| 5.50|
| HOMA-IR | 1.52 | 0.81 | 0.46| 5.27|
| C-peptide (ng/ml) | 1.61 | 0.49 | 0.74| 3.86|
| ALT (U/l) | 14.23 | 6.58 | 6.00| 60.00|
| AST (U/l) | 19.01 | 11.01 | 10.00| 143.00|
| hsCRP (µg/ml) | 1.11 | 1.36 | 0.003| 7.06|
| IL-6 (pg/ml) | 1.04 | 0.96 | 0.08| 6.92|
| Face attractiveness (1–9) | 3.80 | 0.98 | 1.82| 6.32|
| Perceived health (1–9) | 4.81 | 0.74 | 3.17| 7.45|
| BMI (kg/m²) | 22.08 | 3.52 | 16.34| 35.40|
| Estradiol (pg/ml) | 35.55 | 17.69 | 5.00| 110.00|
| tTestosterone (ng/ml) | 0.53 | 0.21 | 0.30| 1.85|

Table 1. Descriptive statistics of the analysed variables ($N = 161$).
(HOMA-IR, C-peptide). PC2 was loaded mainly by lipid profile, mainly markers negatively predicting health (total cholesterol, LDL and triglycerides level). PC3 was loaded mainly by liver enzymes (ALT, AST). PC4 was loaded mainly by inflammatory markers (hsCRP, IL-6). The four PCs jointly explained 69.82% of the variation in health markers variables.

Regression analysis showed that facial attractiveness was mainly predicted by PC2, but unrelated with PC1, PC3 or PC4, when controlled for BMI and sex steroids levels (Table 3).

We found no relationship between perceived health and any of the PCs, when controlled for BMI and sex steroids levels. Perceived health was only predicted by sex steroids levels (Table 4).

**Discussion**

The results of our study showed that facial appearance in healthy women of reproductive age was predicted by lipid profile components, but unrelated with glucose metabolism markers, liver enzyme, and low-grade inflammation markers levels. The results were similar also when controlled for BMI and sex hormones levels. Among lipid parameters, facial attractiveness, but not perceived health, was negatively related with triglycerides, LDL, and total cholesterol (although the latter relationship was not significant when \( p \) was adjusted for multiple testing), but not HDL level. Additionally, we confirmed the negative relationship between facial appearance (attractiveness and health) and BMI and testosterone levels (although the relationship was not significant when \( p \) was adjusted for multiple testing) and positive with estradiol level, reported in previous research3,46,56,57.

Distinct lipid profile components are differently related with health risks60,61 and women’s reproductive functions30. Cholesterol, LDL and triglycerides increase, whereas HDL decreases, the risk of cardiovascular diseases, health problems, and mortality60,61. We found that facial attractiveness was predicted by components detrimental for health and unrelated with relatively protective for health HDL. This result aligns with the “avoidance of bad genes” hypothesis64. From an adaptive view, it might be more important to be more vigilant to and to avoid cues of compromised health and reduced fitness, than look for a perfectly healthy partner, who may be difficult, or even impossible, to be found. This may drive a stronger negative relationship between attractiveness and compromised health and weaker positive relationship between attractiveness and improved health.

We hypothesized that the relationship between facial appearance and lipid profile may be driven by its impact on current and future health and/or by its role as a substrate for sex hormones synthesis30, which have been shown to be related with facial appearance4,17,46. However, although we confirmed the relationship between sex steroids and facial appearance, the lipid profile was only related with facial attractiveness and unrelated with facial health, and presumably it was not the level of sex hormones that explained the relationship between facial attractiveness and lipid profile, but rather BMI, negatively related with both, perceived facial attractiveness and health, but also lipid profile markers (whereas sex steroids were not related with lipid profile). Dyslipidaemia is one of the most common health consequences of excessive body adiposity49, and thus facial appearance in women with high BMI may be the key morphological cue of imbalanced lipid profile (and also other health problems) linked to excessive adiposity level. Similarly, Phalane et al.49 showed that facial attractiveness is a cue to an individual’s health, as it
correlates with immune system functioning, and even more strongly with BMI, a common measure of general health, related also with immunity\textsuperscript{22}. Possibly, sexual selection mechanisms shaped stronger aversion against morphological cues related with many health and fertility problems (not only dyslipidaemia or lower immunity), such as higher body adiposity, rather than against cues of specific health problems. Thus, the relationship between specific health problems and physical attractiveness may remain weaker, potentially resulting in ambiguous results of the studies, employing only selected, not comprehensive measures of health\textsuperscript{7,17,18}, whereas the negative relationship between facial adiposity and perceived attractiveness has been observed cross-culturally\textsuperscript{18,50,67}.

We found no relationship between facial appearance and glucose homeostasis or liver functioning parameters. Previous research showed that glucose level is positively related with perceived age in elderly individuals\textsuperscript{39}, an important predictor of facial attractiveness in women\textsuperscript{9} but we failed to find similar effect in relatively young and healthy women, that participated in our study. Possibly the relationship between attractiveness and these health markers can only be detected in individuals of older age or when comparing healthy individuals with individuals with serious health problems, resulting in chronic increased glucose levels or liver transaminases (but not comparing individuals within normal range of these health markers). This presumption has been somehow confirmed in the previous study showing no correlation between facial attractiveness and health when teen photos were evaluated, whereas more attractive elderly people were assessed also as healthier than their peers\textsuperscript{68}.

Furthermore, although in this research facial attractiveness and health assessments were strongly correlated, the relationships between these two ratings and health biomarkers levels differed. Except for BMI and sex steroids, perceived facial health was only weakly related with hsCRP level (with \( p \) value non-significant after adjustment for multiple testing). Also, facial health ratings were higher compared with facial attractiveness ratings, possibly indicating that health perception is less evolutionary relevant compared to attractiveness perception, as in mate choice individuals choose potential partners based on rather automatic and more strict/determined aesthetic preference (perceived attractiveness) and not based on rather conscious and less strict/determined assessment of health. However, this presumption is only speculative and would require further studies to verify it.

Some limitations of our study need to be addressed as well. First, metabolic health markers and sex steroid hormones levels were assessed only at the between-subjects level, based on a single measurement. Thus, it would be worth to verify the results of our study with repeated metabolic markers and sex steroids measurements, using a longitudinal, rather than cross-sectional design to assess the relationship between metabolic health markers and a woman’s appearance. Another potential limitation is the self-reported moment of menstrual cycle, not confirmed by an objective test. Although women were instructed to visit the lab in the exact days of menstrual cycle and were repeatedly reminded that the date of the visit can be rescheduled, according to a participant’s menstrual cycle pattern, we cannot exclude the possibility that some participants visited the lab at some other day of the menstrual cycle. Future work would benefit from using repeated hormone tests to confirm the moment of the menstrual cycle.

The results of our study suggest, that for healthy women, at a peak of reproductive age, BMI and sex hormones levels may be better predictors of their biological condition, reflected in the level of physical attractiveness, as they are strongly linked to current health and fecundity\textsuperscript{22,68}, although for no relationship between sex steroids and facial attractiveness in women see also\textsuperscript{25} compared to specific measures of metabolic health, such as markers of lipid and glucose homeostasis, liver functioning or low-grade inflammation. Within clinical norm, these measures of health, assessed in relatively young women, without any chronic health problems, may be rather indicators of future health problems, of lesser importance in mating context and only modestly reflected in facial appearance.

Received: 28 January 2020; Accepted: 15 July 2020
Published online: 03 August 2020

References
1. Andersson, M. B. Sexual Selection. (Princeton University Press, Princeton, 1994).
2. Thornhill, R. & Gangestad, S. W. Facial morphine dimorphism, developmental stability, and susceptibility to disease in men and women. Evol. Hum. Behav. 27, 131–144 (2006).
3. Law Smith, M. J. et al. Facial appearance is a cue to oestrogen levels in women. Proc. R. Soc. B Biol. Sci. 273, 135–140 (2005).
4. Rhodes, G., Chan, J., Zebrowitz, L. A. & Simmons, L. W. Does sexual dimorphism in human faces signal health? Proc. R. Soc. B Biol. Sci. 270, S93–S95 (2003).
5. Hönekopp, J., Bartholomé, T. & Jansen, G. Facial attractiveness, symmetry, and physical fitness in young women. Hum. Nat. 15, 147–167 (2004).
6. Rhodes, G. et al. Do facial averageness and symmetry signal health? Evol. Hum. Behav. 22, 31–46 (2001).
7. Foo, Y. Z., Simmons, L. W. & Rhodes, G. Predictors of facial attractiveness and health in humans. Sci. Rep. 7, 39731 (2017).
8. Fink, B., Grammer, K. & Thornhill, R. Human (Homo sapiens) facial attractiveness in relation to skin texture and colour. J. Comp. Psychol. 115, 92 (2001).
9. Fink, B., Grammer, K. & Matts, P. J. Visible skin colour distribution plays a role in the perception of age, attractiveness, and health in female faces. Evol. Hum. Behav. 27, 433–442 (2006).
10. Zahavi, A. Mate selection—A selection for a handicap. J. Theor. Biol. 53, 205–214 (1975).
11. Henderson, A. J., Holzleitner, I. J., Tälamas, S. N. & Perrett, D. I. Perception of health from facial cues. Philos. Trans. R. Soc. B Biol. Sci. 371, 20150380 (2016).
12. Coetzee, V., Re, D., Perrett, D. I., Tiddeman, B. P. & Xiao, D. Judging the health and attractiveness of female faces: Is the most attractive level of facial adiposity also considered the healthiest? Body Image 8, 190–193 (2011).
13. Jones, B. C., Little, A. C., Burt, D. M. & Perrett, D. I. When facial attractiveness is only skin deep. Perception 33, 569–576 (2004).
14. Rhodes, G., Simmons, L. W. & Peters, M. Attractiveness and sexual behavior: Does attractiveness enhance mating success? Evol. Hum. Behav. 26, 186–201 (2005).
15. Scheib, J. E., Gangestad, S. W. & Thornhill, R. Facial attractiveness, symmetry and cues of good genes. Proc. R. Soc. Lond. B Biol. Sci. 266, 1913–1917 (1999).
16. Stephen, I. D., Smith, M. J. L., Stirrat, M. R. & Perrett, D. I. Facial skin coloration affects perceived health of human faces. **Int. J. Primatol.** 30, 845–857 (2009).

17. Rantala, M. J. et al. Facial attractiveness is related to women's cortisol body and core temperature, but not with immune responsiveness. **Biol. Lett.** 9, 20130255 (2013).

18. Hume, D. K. & Montegomery, R. Facial attractiveness signals different aspects of "quality" in women and men. **Evol. Hum. Behav.** 22, 93–112 (2001).

19. Rantala, M. J. et al. Adiposity, compared with masculinity, serves as a more valid cue to immunocompetence in human mate choice. **Proc. R. Soc. Lond. B: Biol. Sci.** 280, 20122495 (2013).

20. Phalane, K. G., Tribe, C., Steel, H. C., Cholo, M. C. & Coetzee, V. Facial appearance reveals immunity in African men. **Sci. Rep.** 7, 7443 (2017).

21. Gangestad, S. W., Merriman, L. A. & Thompson, M. E. Men's oxidative stress, fluctuating asymmetry and physical attractiveness. **Anim. Behav.** 80, 1005–1013 (2010).

22. Cai, Z. et al. No evidence that facial attractiveness, femininity, averageness, or coloration are cues to susceptibility to infectious illness in a university sample of young adult women. **Evol. Hum. Behav.** 40, 156–159 (2019).

23. Gray, A. W. & Boothroyd, L. G. Female facial appearance and health. **Evol. Psychol.** 10, 147470491201000100 (2012).

24. Little, A. C., McPherson, J., Dennington, L. & Jones, B. C. Accuracy in assessment of self-reported stress and a measure of health from static facial information. **Pers. Indiv. Diff.** 51, 693–698 (2011).

25. Weeden, J. & Sabini, J. Physical attractiveness and health in Western societies: a review. **Psychol. Bull.** 131, 635 (2005).

26. Nedelev, J. L. & Beaver, K. M. Physical attractiveness as a phenotypic marker of health: An assessment using a nationally representative sample of American adults. **Evol. Hum. Behav.** 35, 456–463 (2014).

27. Jasińska, G., Bribiescas, R. G., Furgberg, A. S., Helle, S., & Núñez-de la Mora, A. Human reproduction and health: An evolutionary perspective. **Lancet** 390, 510–520 (2017).

28. Wells, I. C., Nesse, R. M., Sear, R., Johnston, R. A. & Stearns, S. C. Evolutionary public health: Introducing the concept. **Lancet** 390, 500–509 (2017).

29. Yesilaltay, A. et al. Excess cholesterol induces mouse egg activation and may cause female infertility. **Proc. Natl. Acad. Sci.** 111, E4972–E4980 (2014).

30. Daniels, T. F., Killinger, K. M., Michal, J. J., Wright, R. W. Jr. & Jiang, Z. Lipoproteins, cholesterol homeostasis and cardiac health. **Int. J. Biol. Sci.** 5, 474 (2009).

31. Lipson, S. F. & Ellison, P. T. (1996). Comparison of salivary steroid profiles in naturally occurring conception and non-conception cycles. **Hum. Reprod.** 11, 2090–2096 (1996).

32. van Montfoort, A. P., Plösch, T., Hoek, A. & Tietge, U. J. Impact of maternal cholesterol metabolism on ovarian follicle development and fertility. **J. Reprod. Immunol.** 104, 32–36 (2014).

33. Seshasai, S. R. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. **N. Engl. J. Med.** 364, 829–841 (2011).

34. Rozing, M. P. et al. Human insulin/IGF-1 and familial longevity at middle age. Aging 1, 714 (2009).

35. Rozing, M. P. et al. Favorable glucose tolerance and lower prevalence of metabolic syndrome in offspring without diabetes mellitus of nonagenarian siblings: The Leiden longevity study. **J. Am. Geriatr. Soc.** 58, 564–569 (2010).

36. Weidentörpfl, R. G. et al. Nonagenarian siblings and their offspring display lower risk of mortality and morbidity than sporadic nonagenarians: The Leiden Longevity Study. **J. Am. Geriatr. Soc.** 57, 1634–1637 (2009).

37. Blazer, S. et al. High glucose-inducing replicative senescence: point of no return and effect of telomerase. **Biochem. Biophys. Res. Commun.** 296, 93–101 (2002).

38. Dekker, P. et al. Stress-induced responses of human skin fibroblasts in vitro reflect human longevity. **Aging Cell** 8, 595–603 (2009).

39. Noordam, R. et al. High serum glucose levels are associated with a higher perceived age. **Age 35, 189–195 (2013).**

40. Dogra, S. & Jindal, R. Cutaneous manifestations of common liver diseases. **J. Clin. Exp. Hepatol.** 1, 177–184 (2011).

41. Gholam, S. H. & Kibbi, A. G. Cutaneous manifestations of liver diseases. **Clin. Dermatol.** 26, 274–282 (2008).

42. Danesh, J. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. **BMJ** 321, 199–204 (2000).

43. Harsoun, G. K. Inflammation, atherosclerosis, and coronary artery disease. **N. Engl. J. Med.** 352, 1685–1695 (2005).

44. Jabbour, H., Sales, K., Catalano, R. & Norman, J. Inflammatory pathways in female reproductive health and disease. **Reproduction** 138, 903–919 (2009).

45. Michaud, M. et al. Proinflammatory cytokines, aging, and age-related diseases. **J. Am. Med. Dir. Assoc.** 14, 877–882 (2013).

46. Probst, F., Bobst, C. & Lobmaier, J. S. Testosterone-to-oestradiol ratio is associated with female facial attractiveness. **Q. J. Exp. Psychol.** 69, 89–99 (2016).

47. Bales, A. C. In search of lipid balance in older women. New studies raise questions about what works best. **Postgrad. Med.** 108, 57 (2000).

48. Cagnacci, A., Paolotti, A. M., Arangino, S., Melis, G. B. & Volpe, A. Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. **Hum. Reprod.** 14, 893–897 (1999).

49. Finstad, S. E. et al. Adult height, insulin, and 17β-estradiol in young women. **Cancer. Epidemiol. Biomarkr.** 18, 1477–1483 (2009).

50. Kilim, S. R., Chandala, S. R. A comparative study of lipid profile and oestradiol in pre-and post-menopausal women. **J. Clin. Diagn. Res.** JCDR 7, 1596 (2013).

51. Arora, M. K., Seth, S., & Dayal, S. The relationship of lipid profile and menstrual cycle with acne vulgaris. **Clin. Biochem.** 43, 1415–1420 (2010).

52. Pulido, J. M. E., & Salazar, M. A. Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle. **Arch. Med. Res.** 30, 19–22 (1999).

53. Lai, C. W. et al. Rhythmic fluctuations in levels of liver enzymes during menstrual cycles of healthy women and effects of body weight. **Clin. Gastroenterol. Hepatol.** (2019) (in press).

54. Mumford, S. L., Dasharathy, S. & Pollack, A. Z. Variations in lipid levels according to menstrual cycle phase: Clinical implications. **Clin. Lipidol.** 6, 225–234 (2011).

55. Schistad, M., Nyberg, E. F., Islam, S. L., & Slaad, A. F. Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women. Epidemiol. Rev. 36, 71–82 (2014).

56. Coetzee, V., Perrett, D. I. & Stephen, I. D. Facial adiposity: A cue to health. **Perception** 38, 1700–1711 (2009).

57. Han, C., Hahn, A. C., Fisher, C. I., Debruijn, L. M. & Jones, B. C. Women's facial attractiveness is related to their body mass index but not their salivary cortisol. **Am. J. Hum. Biol.** 28, 352–355 (2016).

58. Fransen, R., Monajemi, H., Strees, E. S. & Kastelein, J. J. Obesity and dyslipidemia. **Med. Clin. N. Am.** 95, 893–902 (2011).

59. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. **J. R. Stat. Soc. Ser. B Methodol.** 57, 289–300 (1995).

60. Albers, J., J. S. et al. Flare of C-reactive protein during menstrual phase: The strong heart study. **Diabetes Care** 40, 529–537 (2017).

61. Barnett, J. R. et al. Plasma lipid and lipoprotein levels during the follicular and luteal phases of the menstrual cycle. **J. Clin. Endocr. Metab.** 89, 776–782 (2004).
Acknowledgements
This work was supported by National Science Centre, Poland; Grant number 015/19/B/NZ8/02061.

Author contributions
A.Ż., J.N. and B.P. designed the study. A.Ż. and J.N. carried out the experiment and P.L. helped in data collection. B.P. supervised the project. A.Ż. wrote the manuscript with support from J.N., B.P., and P.L. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-70119-6.

Correspondence and requests for materials should be addressed to A.Ż.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020